Genomic Health Announces Fourth Quarter and Year-end 2006 Financial Results and 2007 Full-year Financial Guidance
Tuesday February 6, 4:02 pm ET
- Continued Revenue Growth and Reimbursement Progress -
- Colon Cancer Test Service Advances in Clinical Development -
- Conference Call Today at 4:30 p.m. ET -
REDWOOD CITY, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX - News) today reported financial results for the fourth quarter and year ended December 31, 2006.
Total revenue increased to $8.6 million in the fourth quarter of 2006 compared to $1.9 million in the fourth quarter of 2005. Total revenue for the year ended December 31, 2006 increased to $29.2 million compared to $5.2 million in 2005. Product revenue from Oncotype DX was $8.1 million in the fourth quarter of 2006 compared to $1.9 million in the fourth quarter of 2005. Product revenue was $27.0 million for the year ended December 31, 2006 compared to $4.8 million in 2005.
During the fourth quarter of 2006, approximately 51 percent of product revenue was recorded on an accrual basis and recognized at the time the test service results were delivered, reflecting established payment patterns from payors with coverage policies in place. The balance of product revenue was recognized upon cash collection. Contract revenue was $0.6 million in the fourth quarter of 2006 compared to $0.1 million in the fourth quarter of 2005, and $2.2 million for the year ended December 31, 2006 compared to $0.4 million in 2005.
"We saw steady revenue growth and business progress in 2006, driven by continued clinical progress and significant growth in adoption as well as reimbursement. We entered 2006 with just over 10 million lives covered; now, in early 2007, nearly 100 million lives are covered for Oncotype DX," said Randy Scott, Ph.D., Chairman and Chief Executive Officer of Genomic Health. "We also plan to continue to invest in our promising pipeline. Based on clinical data, we recently selected our program in colon cancer to advance in clinical development. We also are expanding our work in breast cancer to include studies in node-positive patients, as well as evaluating the clinical utility of certain individual Oncotype DX genes to further enhance the value provided by Oncotype DX."
Additional Fourth Quarter 2006 and Year-end 2006 Financial Results
Cost of product revenue was $2.7 million in the fourth quarter of 2006, compared to $1.7 million for the fourth quarter of 2005. Test service volume in the fourth quarter of 2006 was more than double that of the fourth quarter of 2005. The cost per test service delivered again decreased in the quarter compared to the comparable period in 2005. Cost of product revenue for the year ended December 31, 2006 was $9.9 million, compared to $6.2 million in 2005.
Research and development expenses for the fourth quarter of 2006 were $4.2 million compared to $2.5 million for the same period in 2005. Research and development expenses for the full year 2006 were $12.8 million as compared to $9.5 million in 2005. Selling and marketing and general and administrative expenses for the fourth quarter of 2006 were $11.2 million, compared to $6.5 million for the same period in 2005. Selling and marketing and general and administrative expenses in 2006 were $37.4 million compared to $21.8 million in 2005.
Net loss was $9.0 million in the fourth quarter of 2006 compared to $8.2 million in the fourth quarter of 2005. Basic and diluted net loss per share applicable to common stockholders was $0.37 in the fourth quarter of 2006 compared to a $0.34 net loss per share in the fourth quarter of 2005.
Net loss for the year ended December 31, 2006 was $28.9 million compared to $31.4 million in 2005. Basic and diluted net loss per share was $1.18 for the year ended December 31, 2006 compared to a $4.15 net loss per share in 2005. On a pro forma basis, basic and diluted net loss per share was $1.18 per share for the year ended December 31, 2006 versus $1.31 net loss per share for the same period in 2005.
Cash and Cash Equivalents
Cash and cash equivalents and investments at December 31, 2006 were $44.2 million, compared to $69.5 million at December 31, 2005 and $48.3 million at September 30, 2006.
Recent Highlights and Accomplishments
Peer-Reviewed Publications and Medical Meeting Presentations
Multiple new findings on Oncotype DX were presented at the 29th Annual San Antonio Breast Cancer Symposium (SABCS):
* The National Surgical Adjuvant Breast and Bowel Project (NSABP)
presented findings from an assessment of three methods to measure
estrogen receptor gene expression, which demonstrated that Oncotype DX
had the strongest correlation to distant recurrence, or length of time
following treatment before a cancer returns.
* The company announced multiple new findings based on over 20,000 tumor
samples. Data revealed considerable heterogeneity within three major
subtypes of breast cancer, and separately, showed that the expression of
proliferation genes is largely independent of the hormone and growth
factor receptor genes. The company believes these data underscore the
importance of standardized measurement of gene expression as a clinical
tool.
* NSABP and Kaiser Permanente presented results of a study that used
Oncotype DX to clarify the distinct roles of hormone receptor genes in
breast cancer, which indicated that not all women with estrogen
receptor-positive breast cancer benefit equally from tamoxifen.
* An analysis of more than 10,000 node-negative tumors conducted by
Genomic Health researchers indicated that all 21 genes in the Oncotype
DX gene panel impact the Recurrence Score of an individual woman's
tumor.
Pipeline
* We are advancing the clinical development of a test service to predict
the likelihood of colon cancer recurrence. The company intends to follow
a similar clinical development path for its colon cancer assay as it did
with its Oncotype DX breast cancer test service. If successful, studies
in 2007 could lead to a validation study in 2008, followed by a
commercial launch in 2009.
* Following data presented at SABCS on single genes, the company is
conducting additional studies to evaluate the clinical utility of
individual Oncotype DX genes. If successful, the company plans to
include single gene results for estrogen receptor and progesterone
receptor gene expression by the end of 2007.
* The company's work in node-positive breast cancer continues, with
additional studies planned for 2007, which, if successful, may yield a
commercial product in 2008.
Physician Usage and Adoption
* More than 4,450 test services were delivered in the fourth quarter of
2006 compared to more than 2,100 test services delivered in the fourth
quarter of 2005.
* More than 14,500 test services were delivered in 2006 compared to over
7,000 in 2005.
* Over 5,000 physicians have ordered a cumulative total of more than
21,500 test services for their patients.
* During the first quarter of 2007, the company plans to expand its direct
field sales force to a total of 50.
Reimbursement Progress
* In January, UnitedHealthcare signed a national payor contract
establishing coverage for Oncotype DX across all of its plans. This
followed the national payor contract with Aetna announced in the fourth
quarter of 2006.
* A number of additional regional payors have established policies to
reimburse for Oncotype DX test services, including Blue Cross of South
Carolina, Blue Cross of Minnesota, Mountain State Blue Cross covering
West Virginia, and CareFirst, covering Blue Cross of Delaware, Maryland
and District of Columbia.
Regulatory
* Genomic Health continues its ongoing dialogue with FDA regarding the
Oncotype DX breast cancer assay service. The company is evaluating
FDA's draft guidance on "In Vitro Diagnostic Multivariate Index Assays,"
which was distributed for public comment, and it intends to submit
comments prior to the March 5, 2007 deadline.
2007 Financial Guidance
The Company is providing the following financial guidance for the full year ending December 31, 2007:
* Test Results Delivered: 23,000 to 25,000.
* Revenue: $57 million to $63 million.
* Net Loss: $27 million to $30 million.
The above guidance assumes that the company continues to successfully obtain reimbursement from national providers. Quarter-to-quarter fluctuation is expected in reported revenue. Gross margin on product revenue for 2007 is anticipated to continue to improve and exceed 70 percent of sales for the full year. The guidance reflects the company's continued investment in its research and development programs and facilities, and expansion of its field sales organization.
Conference Call Details
To access the live conference call today, February 6 at 4:30 p.m. Eastern Time via phone, please dial (877) 356-8064 from the United States and Canada or (706) 758-4314 internationally. The conference ID is 6775232. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through February 13 and may be accessed by dialing (800) 642-1687 from the United States and Canada or (706) 645-9291 internationally. The replay passcode is 6775232.
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company's website at investor.genomichealth.com . Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.
About Genomic Health
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the continued growth in adoption of and reimbursement for our test service; our plans to invest in our product pipeline, our plans to pursue and advance the clinical development for our colon cancer and node-positive breast cancer assays, the timing of a validation study or commercialization of our colon cancer or node-positive breast cancer assays, the outcome or success of clinical trials, our belief that the increase in adoption underscores the oncology community's growing support for our test service and the value it provides to patients and physicians; the applicability of clinical study results to actual outcomes; our intention to conduct additional studies on single genes and to provide single gene reporting for certain genes as part of the current Oncotype DX reports; our intention to expand our direct field sales personnel; our intention to submit comments on FDA's draft guidance; and our 2007 financial guidance, including expectations regarding the number of test results delivered, revenue, net loss and gross margin. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our ability to increase usage of our test services; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing test service and any future services we may develop; the risks and uncertainties associated with the regulation of our test services by FDA; our ability to compete against third parties; our ability to develop and commercialize new test services; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward- looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
Genomic Health, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
For the For the
Three Months Ended Year Ended
December 31, December 31,
2006 2005 2006 2005
(Unaudited) (Unaudited) (Audited)
REVENUES:
Product revenues $8,074 $1,863 $27,006 $4,823
Contract revenues 542 62 2,168 379
Total revenues 8,616 1,925 29,174 5,202
OPERATING EXPENSES:
Cost of product revenues 2,707 1,729 9,908 6,249
Research and development 4,162 2,494 12,841 9,465
Selling and marketing 7,295 4,543 24,625 15,348
General and administrative 3,861 1,974 12,765 6,485
Total operating expenses 18,025 10,740 60,139 37,547
Operating loss (9,409) (8,815) (30,965) (32,345)
Other income (expense):
Interest income 548 693 2,480 1,241
Interest expense (134) (95) (446) (258)
Other income -- -- 11 1
Net loss ($8,995) ($8,217) ($28,920) ($31,361)
Basic and diluted
net loss per share ($0.37) ($0.34) ($1.18) ($4.15)
Shares used to compute
basic and diluted
net loss per share 24,537,122 23,904,747 24,508,845 7,557,106
Pro forma basic and diluted
net loss per share ($0.34) ($1.31)
Shares used to compute
pro forma basic and diluted
net loss per share 24,455,518 23,991,612
Genomic Health, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
As of As of
31-Dec-06 31-Dec-05
(Unaudited) (Audited)
Cash and cash equivalents $14,926 $18,839
Short term investments 29,289 50,688
Accounts receivable 1,862 314
Prepaid expenses and other current assets 1,609 1,621
Total current assets 47,686 71,462
Property and equipment, net 9,421 3,597
Restricted cash 500 500
Other assets 417 240
Total assets $58,024 $75,799
Accounts payable $2,046 $1,393
Other current liabilities 6,029 2,978
Deferred revenue 847 238
Capital leases, short-term 2,547 1,052
Capital leases, long-term 4,726 2,621
Stockholder's equity 41,829 67,517
Total liabilities and stockholders' equity $58,024 $75,799
Source: Genomic Health, Inc. |
